|Bid||0.00 x 0|
|Ask||0.00 x 0|
|Day's range||19.56 - 20.89|
|52-week range||16.50 - 21.54|
|Beta (5Y monthly)||0.40|
|PE ratio (TTM)||18.30|
|Forward dividend & yield||1.09 (5.46%)|
|Ex-dividend date||18 Nov 2021|
|1y target est||N/A|
Novavax (NVAX) begins evaluating its COVID-19 vaccine against the Omicron variant. The company also starts developing an Omicron-specific COVID-19 vaccine.
GSK vs. NVO: Which Stock Is the Better Value Option?
Glaxo (GSK) and Vir Biotechnology announce promising pre-clinical data from the study of their antibody candidate, sotrovimab, against mutations found in the Omicron variant.